Prevalence of Second Primary Malignancies in Patients With Well-Differentiated Neuroendocrine Tumors

IF 3.7 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Endocrine Practice Pub Date : 2025-04-01 DOI:10.1016/j.eprac.2024.12.020

Kosma Woliński MD, PhD, Paweł Komarnicki MD, Adam Maciejewski MD, PhD, Jan Musiałkiewicz MD, Paweł Gut MD, PhD, Marek Ruchała MD, PhD

{"title":"Prevalence of Second Primary Malignancies in Patients With Well-Differentiated Neuroendocrine Tumors","authors":"Kosma Woliński MD, PhD, Paweł Komarnicki MD, Adam Maciejewski MD, PhD, Jan Musiałkiewicz MD, Paweł Gut MD, PhD, Marek Ruchała MD, PhD","doi":"10.1016/j.eprac.2024.12.020","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Neuroendocrine tumors (NETs) constitute a diverse group of tumors. NETs are often diagnosed late, due to nonspecific symptoms. Second Primary Malignancies (SPMs) have been reported in up to 25% of NETs and their incidence has been described as negative predictor of overall survival. We aimed to assess the prevalence of SPMs in patients with NETs treated at a specialized center.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of patients with metastatic well-differentiated gastro-entero-pancreatic neuroendocrine tumors and lung carcinoids treated with Somatostatin Analogs between 2017 and 2019. Control group patients with hormonally inactive pituitary lesions and microprolactinomas hospitalized between 2016 and 2019 were included.</div></div><div><h3>Results</h3><div>One hundred thirty-five patients (85 women, 50 men) with NETs were enrolled. SPMs were more common in NETs compared to control group (<em>P</em> = .029). Twenty-six SPMs were diagnosed in 24 patients (17.8%). The control group comprised 94 patients, among whom 7 patients (7.7%) developed SPMs. Mean (standard deviation) age at the end of follow-up was 64.8 (10.2) years, with duration from NETs diagnosis to the end of follow-up of 5.3 (3.8) years.</div></div><div><h3>Conclusion</h3><div>The risk of SPMs is high in NETs, with multiple neoplasms diagnosed in over one sixth of patients. Active surveillance for SPMs is strongly indicated and should be integral to the follow-up of NETs.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"31 4","pages":"Pages 426-432"},"PeriodicalIF":3.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine Practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1530891X25000011","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Neuroendocrine tumors (NETs) constitute a diverse group of tumors. NETs are often diagnosed late, due to nonspecific symptoms. Second Primary Malignancies (SPMs) have been reported in up to 25% of NETs and their incidence has been described as negative predictor of overall survival. We aimed to assess the prevalence of SPMs in patients with NETs treated at a specialized center.

Methods

We conducted a retrospective analysis of patients with metastatic well-differentiated gastro-entero-pancreatic neuroendocrine tumors and lung carcinoids treated with Somatostatin Analogs between 2017 and 2019. Control group patients with hormonally inactive pituitary lesions and microprolactinomas hospitalized between 2016 and 2019 were included.

Results

One hundred thirty-five patients (85 women, 50 men) with NETs were enrolled. SPMs were more common in NETs compared to control group (P = .029). Twenty-six SPMs were diagnosed in 24 patients (17.8%). The control group comprised 94 patients, among whom 7 patients (7.7%) developed SPMs. Mean (standard deviation) age at the end of follow-up was 64.8 (10.2) years, with duration from NETs diagnosis to the end of follow-up of 5.3 (3.8) years.

Conclusion

The risk of SPMs is high in NETs, with multiple neoplasms diagnosed in over one sixth of patients. Active surveillance for SPMs is strongly indicated and should be integral to the follow-up of NETs.

查看原文本刊更多论文

分化良好的神经内分泌肿瘤患者中第二原发恶性肿瘤的患病率。

目的：神经内分泌肿瘤（NETs）是一类种类繁多的肿瘤。由于非特异性症状，NETs往往诊断较晚。第二原发性恶性肿瘤（SPMs）已在高达25%的NETs中报道，其发病率被描述为OS的负预测因子。我们的目的是评估在专门中心接受net治疗的患者中SPMs的患病率。方法：回顾性分析2017年至2019年接受生长抑素类似物治疗的转移性高分化胃-肠-胰腺NETs和肺类癌患者。对照组纳入2016 - 2019年住院的激素无活性垂体病变和微泌乳素瘤患者。结果：135例net患者（85名女性，50名男性）入组。与对照组相比，NETs中SPMs更常见（p=0.029）。24例患者诊断为SPMs 26例（17.8%）。对照组94例，其中7例（7.7%）发生SPMs。随访结束时的平均（SD）年龄为64.8（10.2）岁，从NETs诊断到随访结束的时间为5.3（3.8）年。结论：net患者发生SPMs的风险很高，超过六分之一的患者被诊断为多发性肿瘤。报告强烈指出，应积极监测预防措施，并将其作为蚊帐后续行动的组成部分。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Endocrine Practice ENDOCRINOLOGY & METABOLISM-

CiteScore

7.60

自引率

2.40%

发文量

546

审稿时长

41 days

期刊介绍： Endocrine Practice (ISSN: 1530-891X), a peer-reviewed journal published twelve times a year, is the official journal of the American Association of Clinical Endocrinologists (AACE). The primary mission of Endocrine Practice is to enhance the health care of patients with endocrine diseases through continuing education of practicing endocrinologists.